MDxHealth SA (0O8G.L)

3,0198 -0,1804 (-5,64%) Alla chiusura: 06:16PM BST

MDxHealth SA

CAP Business Center
Rue d’Abhooz 31 Zone Industrielle des Hauts-Sarts
Herstal 4040
Belgium
32 4 257 70 21
https://mdxhealth.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 300

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Michael K. McGarrity	CEO & Executive Director	709,27k	N/D	1963
Mr. Ron Kalfus CPA	Chief Financial Officer	N/D	N/D	1974
Mr. Joseph Sollee J.D., LLM	Executive VP of Corporate Development & General Counsel	N/D	N/D	1965
Mr. John A. Bellano	Chief Commercial Officer	N/D	N/D	1969
Ms. Miriam Reyes	Executive Vice President of Operations	N/D	N/D	1973
Dr. Jason Poole Ph.D.	Chief Scientific Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Governance aziendale

L'ISS Governance QualityScore di MDxHealth SA al 1 luglio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 5; diritti degli azionisti: 1; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.